Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Registry of Drug Industry CME Will Be Proposed By Sen. Kohl

Executive Summary

Legislation to create a national registry of pharmaceutical company funding for continuing medical education and other support to physicians is being drafted by Sen. Herb Kohl, D-Wis

You may also be interested in...



As Drug Marketing Laws Proliferate In States, PhRMA Rejects Federal Option

State laws to restrict how pharmaceutical companies market their products to physicians are not yet so burdensome that industry is ready to support a federal scheme, Pharmaceutical Research and Manufacturers of America VP for Government Affairs Jan Faiks told the Food and Drug Law Institute's advertising and promotion conference Sept. 17

As Drug Marketing Laws Proliferate In States, PhRMA Rejects Federal Option

State laws to restrict how pharmaceutical companies market their products to physicians are not yet so burdensome that industry is ready to support a federal scheme, Pharmaceutical Research and Manufacturers of America VP for Government Affairs Jan Faiks told the Food and Drug Law Institute's advertising and promotion conference Sept. 17

States Boost Oversight Of Rx Marketing; In Vt., Reps Must Discuss “Alternatives”

As of next year, pharmaceutical companies will face tougher restrictions on their marketing activities in Vermont and Nevada, and naturally, the climate in New England will be chillier: The Vermont bill is the more rigorous and comprehensive measure

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel